A single 25-mg dose of a synthetic formulation of psilocybin appears to improve the core symptoms of treatment-resistant depression (TRD), a new analysis of phase 2 trial data suggests.
Despite the growth of psychedelic research, psychedelic-assisted group psychotherapy (PAGP) has received little attention in comparison to individual psychedelic-assisted psychotherapy models.
The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin. The molecular structure of psilocybin, a naturally occurring psychedelic compound found in ‘magic mushrooms,’ allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses.
Backed by $17 million of funding, researchers build on previous work and expand research on psychedelics for illness and wellness: (1) to develop new treatments for a wider variety of psychiatric and behavioral disorders with the aspiration of treatments tailored to the specific needs of individual patients and (2) to expand research in healthy volunteers with the ultimate aspiration of opening new ways to support human thriving.